Loading…
NovoCure Limited is projected to rise to $15.75 by 2027, a +3% move from its current price of $15.23. NVCR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $14.53 | $15.22 | $15.94 | -0.08% |
| Aug 2 | $14.24 | $15.21 | $16.24 | -0.16% |
| Aug 3 | $14.02 | $15.19 | $16.47 | -0.23% |
| Aug 4 | $13.84 | $15.18 | $16.66 | -0.31% |
| Aug 5 | $13.68 | $15.17 | $16.83 | -0.39% |
| Aug 6 | $13.53 | $15.16 | $16.98 | -0.47% |
| Aug 7 | $13.40 | $15.15 | $17.12 | -0.55% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $13.40 | $15.15 | $17.12 | -0.55% |
| Week 2 | $12.66 | $15.06 | $17.92 | -1.09% |
| Week 3 | $12.11 | $14.98 | $18.53 | -1.63% |
| Week 4 | $11.66 | $14.90 | $19.04 | -2.17% |
| Week 5 | $11.26 | $14.82 | $19.50 | -2.70% |
| Week 6 | $10.91 | $14.74 | $19.90 | -3.23% |
| Week 7 | $10.59 | $14.66 | $20.28 | -3.76% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NovoCure Limited is a healthcare company that develops, manufactures, and commercializes tumor treating fields (TTFields) devices for the treatment of solid tumor cancers. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
NovoCure Limited (NVCR) is trading at $16.31, with a market cap of $1.89B and a rank of 2009. These metrics place the stock within a small-cap segment of the healthcare space.
A major floor 35.0% below — a decisive break under it would weaken the trend.
The nearest floor, 10.6% below — buyers have tended to step in here.
The nearest ceiling, 31.3% above — a clean break opens room to run.
A major ceiling 48.8% above — clearing it would confirm fresh momentum.
Key NVCR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NVCR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $16.28 | Sell | $15.99 | Sell |
| MA 10 | $16.48 | Sell | $16.30 | Sell |
| MA 20 | $16.61 | Sell | $16.38 | Sell |
| MA 50 | $16.58 | Sell | $16.13 | Sell |
| MA 100 | $14.88 | Buy | $15.37 | Sell |
| MA 200 | $13.78 | Buy | $14.88 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.45 | Neutral |
| Stoch RSI (14) | 0.63 | Buy |
| CCI (20) | -105.26 | Sell |
| Williams %R (14) | -99.37 | Info |
| MACD (12,26,9) | -0.13 | Sell |
| ROC (12) | -2.06 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 0.63 | Buy |
| TRIX (15) | 0.06 | Buy |
| Awesome (5,34) | -0.02 | Sell |
| Ultimate (7,14,28) | 46.80 | Neutral |
| Momentum (10) | -1.19 | Sell |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 15.51 | Sell |
| ADX (14) | 11.01 | Neutral |
| ATR (14) | 0.79 | Info |
Sentiment: BULLISH. RSI14: 50. SMA50: $16.71. SMA200: $13.74. Support: $13.61. Resistance: $19.99. Thirty-day range: $11.62 to $22.89.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $10.03 | $15.23 | $19.33 | 0% | Neutral | |
| $11.76 | $15.75 | $22.71 | +3% | Neutral | |
| $15.13 | $21.33 | $32.59 | +40% | Bullish | |
| $16.53 | $24.35 | $38.89 | +60% | Bullish | |
| $18.30 | $28.05 | $46.47 | +84% | Bullish | |
| $20.18 | $32.07 | $54.85 | +111% | Bullish | |
| $17.29 | $28.44 | $50.02 | +87% | Bullish | |
| $17.64 | $29.99 | $54.10 | +97% | Bullish | |
| $19.23 | $33.74 | $62.28 | +122% | Bullish | |
| $22.36 | $40.46 | $76.29 | +166% | Bullish | |
| $24.63 | $51.61 | $106.18 | +239% | Bullish | |
| $54.49 | $121.10 | $278.53 | +695% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $10.03 | $15.23 | $17.82 | +0.00% |
| August 2026 | $12.18 | $14.51 | $17.85 | -4.71% |
| September 2026 | $11.73 | $14.18 | $17.83 | -2.29% |
| October 2026 | $12.21 | $14.93 | $19.09 | +5.26% |
| November 2026 | $12.23 | $15.10 | $19.58 | +1.14% |
| December 2026 | $11.82 | $14.72 | $19.33 | -2.52% |
Click any year to see its month-by-month NVCR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, NVCR is projected to trade between $10.03 and $19.33, averaging $15.23 — a potential gain of 0% from today's $15.23. Price action looks broadly range-bound.
NovoCure Limited's 2027 outlook centres on $15.75, within a $11.76 to $22.71 range. That is up +3% on the projected 2026 average. That marks a +3% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, NVCR could reach as high as $32.59, with a base case around $21.33 and support toward $15.13 — roughly +40% from $15.23. Momentum favours further upside here.
Expect NVCR to range from $16.53 to $38.89 through 2029. The $24.35 average target implies a +60% move from current prices. That is up +14% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The NVCR price prediction for 2030 points to an average of $28.05 (low $18.30, high $46.47) — a potential gain of +84% on today's $15.23. Momentum favours further upside here.
In 2031, NVCR is projected to trade between $20.18 and $54.85, averaging $32.07 — a potential gain of +111% from today's $15.23. That is up +14% on the projected 2030 average. Buyers look set to stay in control over this stretch.
NovoCure Limited's 2032 outlook centres on $28.44, within a $17.29 to $50.02 range. That is -11% versus the projected 2031 average. That marks a +87% change versus current levels. Momentum favours further upside here.
By 2033, NVCR could reach as high as $54.10, with a base case around $29.99 and support toward $17.64 — roughly +97% from $15.23. Buyers look set to stay in control over this stretch.
Expect NVCR to range from $19.23 to $62.28 through 2034. The $33.74 average target implies a +122% move from current prices. That is up +13% on the projected 2033 average. Momentum favours further upside here.
The NVCR price prediction for 2035 points to an average of $40.46 (low $22.36, high $76.29) — a potential gain of +166% on today's $15.23. Buyers look set to stay in control over this stretch.
In 2040, NVCR is projected to trade between $24.63 and $106.18, averaging $51.61 — a potential gain of +239% from today's $15.23. That is up +28% on the projected 2035 average. Momentum favours further upside here.
NovoCure Limited's 2050 outlook centres on $121.10, within a $54.49 to $278.53 range. That is up +135% on the projected 2040 average. That marks a +695% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in NVCR today (≈ 65.659882 NVCR) could be worth
$7,951.39
+$6,951.39 (+695%) by 2050 · US Dollar
Based on the average projected NVCR price of $121.1 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NVCRwould be worth at today's price.
$1,000 invested in NVCR on Jul 30, 2025 (≈ 91.157701 NVCR) would be worth
$1,388.33
+$388.33 (+38.8%) today · 1.39× · US Dollar
Based on a NVCR entry price of $10.97 vs. today's $15.23.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.99 | $761.88 | -23.8% |
| 1 month ago | $15.15 | $1,005.28 | +0.5% |
| 3 months ago | $16.62 | $916.37 | -8.4% |
| 6 months ago | $12.4 | $1,228.23 | +22.8% |
| 1 year ago | $10.97 | $1,388.33 | +38.8% |
| All time (5.0y) ago | $150.68 | $101.08 | -89.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NVCR forecast.
Our base-case forecast reaches $30.00 around 2031.
Implied market cap at $30.00: $3.49B
The multi-year forecast shows a bullish trajectory after 2026. The 2026 forecast is min $10.03, avg $16.31, max $20.94 with ROI 0 and sentiment NEUTRAL; 2027 min $12.64, avg $17.25, max $25.40 with ROI 5.7 and sentiment NEUTRAL; 2028 min $16.89, avg $24.44, max $38.33 with ROI 49.8 and sentiment BULLISH. By 2030 the min is $20.61, avg $32.78, max $56.11 with ROI 101 and sentiment BULLISH.
The path extends to 2040 with min $28.46, avg $63.24, max $136.35 and ROI 287.8; 2050 shows min $69.67, avg $154.82, max $356.08 with ROI 849.2 and sentiment BULLISH. These figures illustrate a sustained upside in the schedule, with higher averages and larger max values in the later years, though they remain projections rather than guarantees.
Tap a question to reveal the answer.
In 2030, the forecast shows min $20.61, avg $32.78, max $56.11, ROI 101, sentiment BULLISH.
The forecast indicates a transition to bullish sentiment in 2028 and beyond, with rising average prices and high max values by 2040 and 2050. For example, 2040 is min $28.46, avg $63.24, max $136.35 with ROI 287.8, and 2050 is min $69.67, avg $154.82, max $356.08 with ROI 849.2. These are estimates, not guarantees.
Yes. The forecast shows max values of $136.35 in 2040 and $356.08 in 2050, indicating prices well above $100 in those years.
Current price is $16.31 and market cap is $1.89B.
The 30-day range is $11.62 to $22.89.
NovoCure Limited Community Discussion
0Share your NovoCure Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.